|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/7088 | |
| C07H 21/02 | |||
| A61K 48/00 | |||
| A61K 31/7115 | |||
| A61K 31/713 | |||
| C12N 15/113 | |||
| A61P 27/02 |
| (11) | Number of the document | 3329924 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17187246.8 |
| Date of filing the European patent application | 2011-03-29 | |
| (97) | Date of publication of the European application | 2018-06-06 |
| (45) | Date of publication and mention of the grant of the patent | 2021-05-05 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 318702 P | 2010-03-29 | US | |
| 318704 P | 2010-03-29 | US |
| (72) |
ALVAREZ, Rene, US
SAH, Dinah Wen-Yee, US
ANDO, Yukio, JP
JONO, Hirofumi, JP
|
| (73) |
Kumamoto University,
39-1 Kurokami 2-chome, Kumamoto-shi Kumamoto 860-8555,
JP
Alnylam Pharmaceuticals, Inc., 300 Third Street, 3rd Floor, Cambridge, MA 02142, US |
| (54) | DSRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS |
| DSRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS |